What “okay for long-term use” can responsibly mean

No compound is universally safe for long-term use. The strongest statement is that a specific FDA-approved medication has evidence and labeling for chronic treatment in eligible patients under medical supervision. That conclusion cannot be transferred to an unapproved research product, a different formulation, or a different use.

Semaglutide and tirzepatide have randomized human data extending well beyond a year for approved metabolic indications. Continued-treatment and withdrawal studies also show that stopping can be followed by meaningful weight regain, which supports treating obesity as a chronic condition rather than assuming a short cycle creates a permanent result.

A new 2026 kisspeptin-10 physiology study illustrates the same limit at the short end of the evidence spectrum: sustained hormone changes over 12 days in small groups of healthy men are not evidence for an indefinite-use plan, a generic cycle, or long-term clinical safety.

The middle category: a narrow approval or incomplete duration evidence

Tesamorelin is approved for a specific population—adults with HIV-associated lipodystrophy—but its official labeling says long-term cardiovascular safety has not been established and that it is not indicated for weight-loss management. This is a good example of why “approved” does not mean unrestricted or proven indefinitely for every goal.

Retatrutide has encouraging phase 2 obesity results and a published 40-week phase 3 trial in adults with type 2 diabetes, but it remains investigational while additional later-stage studies continue. Neither a 40-week nor a 48-week trial can settle every long-term safety question, and a research timeline is not a personal treatment recommendation. FDA's current public safety page says retatrutide is not approved, has not been found safe and effective for any condition, and cannot be used in compounding under federal law.

Where evidence does not support a long-term-use claim

For BPC-157, TB-500, CJC-1295, ipamorelin, semax, selank, MOTS-c, injectable GHK-Cu, kisspeptin-10, and many popular blends, available evidence does not establish a generally safe long-term human-use program. FDA has identified missing safety information or potential risks for several of these bulk substances.

That absence of evidence also means there is no scientifically validated on-and-off schedule that makes these products safe. Calling an interval a “cycle” does not replace clinical trials, product approval, quality controls, or individual monitoring.

A better set of questions than “How long is the cycle?”

Ask whether the exact product is FDA approved, whether the intended use matches the approved indication, how long participants were followed, what happened after discontinuation, and which adverse effects or laboratory values require monitoring. Those questions reveal the quality and limits of the evidence without turning a research summary into a treatment plan.

• Approved chronic-treatment evidence: semaglutide- and tirzepatide-containing prescription products for specific labeled indications.
• Narrow approval with explicit long-term limits: tesamorelin for HIV-associated lipodystrophy.
• Investigational with ongoing trials: retatrutide.
• Insufficient evidence for a safe long-term plan or validated cycle: most other research peptides in the S7 catalog.